Huons said Wednesday that it registered 328.6 billion won ($291.9 million) in sales in 2018, a record-high level with a 15 percent increase from the previous year.
|Huons headquarters in Seongnam, Gyeonggi Province|
The company also registered 45.3 billion won in operating profit last year, up 25 percent increase from 2017. Aside from its subsidiaries, Huons Global alone posted 278 billion won in sales, and 48 billion won in operating profit.
“The record-high sale was due to the export of two of our injections -- lidocaine and saline solution-- to the U.S. after FDA’s approval,” the company said. “The ethical drug division, which is the company’s flagship business, also maintained stable growth of 18 percent helping to boost profitability.”
The reflection of the 8 billion sales made by Huons Nature, which was acquired last year, on the company’s annual earnings has also contributed to the company’s growth, it added.
This year, Huons plans to add corrective and preventive actions for its eye drop, as well as new business models such as diabetes medical device and health functional foods. The company is also waiting for the approval of Liztox, its botulinum toxin product, this year.
“Huons achieved positive results last year in all business segments, from specialty medicines to contract manufacturing organization and health functional foods,” Huons CEO Um Key-an said. “This year the company will continue to make concrete achievements.”
<© Korea Biomedical Review, All rights reserved.>